Birato

Birato

abiraterone

Manufacturer:

Mega Lifesciences
Concise Prescribing Info
Contents
Abiraterone acetate
Indications/Uses
In combination w/ prednisone or prednisolone for the treatment of metastatic prostate cancer in asymptomatic or mildly symptomatic patients after failure of androgen deprivation therapy (ADT) or have received prior chemotherapy containing taxane; w/ androgen deprivation therapy & prednisone or prednisolone is indicated for the treatment of adult men w/ newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC).
Dosage/Direction for Use
1,000 mg as a single daily dose.
Administration
Should be taken on an empty stomach: Take at least 1 hr before or 2 hr after meals. Swallow whole, do not chew/crush.
Contraindications
Hypersensitivity. Severe hepatic impairment. Pregnancy.
Special Precautions
HTN, hypokalemia & fluid retention due to mineralocorticoid excess.
MIMS Class
Cancer Hormone Therapy
ATC Classification
L02BX03 - abiraterone ; Belongs to the class of other hormone antagonists and related agents. Used in the treatment of metastatic castration-resistant prostate cancer.
Presentation/Packing
Form
Birato tab 250 mg
Packing/Price
120's (Rp7,000,000/botol)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in